Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
122
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

251
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
251
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
253
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Psoriasiform Dermatitis Using Systemic Biologics and Small Molecules: An Evidence-Based Review.

Journal of cutaneous medicine and surgery·2026
Same author

Cutaneous adverse events with immune checkpoint inhibitors in Paediatric patients: A meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Patient-Clinician Communication Skills in Dermatology: A Systematic Review.

Journal of cutaneous medicine and surgery·2026
Same author

Treatments for Recurrent Herpes Labialis: A Systematic Review of Randomized Controlled Trials.

Journal of cutaneous medicine and surgery·2026
Same author

Laser and Energy-Based Device Treatments for Melasma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of cutaneous medicine and surgery·2026
Same author

Treatments for Molluscum contagiosum: A systematic review.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Related Experiment Video

Updated: Jun 14, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K

Biologic and Small Molecule Therapy in Atopic Dermatitis.

Mahek Shergill1, Barinder Bajwa2, Orhan Yilmaz3

  • 1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8P 1H6, Canada.

Biomedicines
|August 29, 2024
PubMed
Summary

Atopic dermatitis treatments are evolving, with new biologics and small molecules offering targeted approaches. This review details current and emerging therapies for managing this chronic inflammatory skin condition.

Keywords:
ADJAK1JAK2JAK3Janus kinase inhibitorsTYK2dupilumab

More Related Videos

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.4K
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.4K

Related Experiment Videos

Last Updated: Jun 14, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.4K
A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.4K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis is a prevalent chronic inflammatory skin disease.
  • It results from complex genetic, immunological, and environmental interactions.
  • Rising incidence necessitates novel therapeutic strategies.

Purpose of the Study:

  • To review current and emerging treatments for atopic dermatitis.
  • To analyze mechanisms of action, clinical trials, efficacy, and safety.
  • To explore targeted therapies like biologics and small molecules.

Main Methods:

  • Literature review of existing and novel atopic dermatitis therapies.
  • Analysis of therapeutic agents including emollients, corticosteroids, and immunosuppressants.
  • Examination of biologics and small molecule inhibitors.

Main Results:

  • Current therapies include emollients, corticosteroids, and systemic agents.
  • Biologics such as dupilumab and tralokinumab target specific inflammatory pathways.
  • Small molecules include JAK inhibitors and PDE4 inhibitors, offering new treatment avenues.

Conclusions:

  • Atopic dermatitis management is advancing with targeted biologics and small molecules.
  • These newer agents offer improved efficacy and safety profiles.
  • Further research into novel therapeutic targets is ongoing.